KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Financing Activities (2016 - 2025)

Travere Therapeutics' Cash from Financing Activities history spans 13 years, with the latest figure at $26.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 80.82% year-over-year to $26.7 million; the TTM value through Dec 2025 reached -$33.5 million, down 124.0%, while the annual FY2025 figure was -$33.5 million, 124.0% down from the prior year.
  • Cash from Financing Activities reached $26.7 million in Q4 2025 per TVTX's latest filing, up from -$65.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $217.0 million in Q1 2023 to a low of -$65.3 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $34.1 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 9137.65% in 2024, then plummeted 142141.3% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $39.3 million in 2021, then tumbled by 98.6% to $551000.0 in 2022, then surged by 173.32% to $1.5 million in 2023, then soared by 9137.65% to $139.1 million in 2024, then plummeted by 80.82% to $26.7 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Cash from Financing Activities are $26.7 million (Q4 2025), -$65.3 million (Q3 2025), and $1.5 million (Q2 2025).